Invention Grant
- Patent Title: Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
-
Application No.: US13980180Application Date: 2012-01-19
-
Publication No.: US10222377B2Publication Date: 2019-03-05
- Inventor: Heidi Alexandra Lane , Felix Bachmann , Madlaina Breuleux , Michael Boutros , Daniel Gilbert , Xian Zhang
- Applicant: Heidi Alexandra Lane , Felix Bachmann , Madlaina Breuleux , Michael Boutros , Daniel Gilbert , Xian Zhang
- Applicant Address: CH Basel DE Heidelberg
- Assignee: BASILEA PHARMACEUTICA AG,RUPRECHT-KARLS-UNIVERSITAT-HEIDELBERG
- Current Assignee: BASILEA PHARMACEUTICA AG,RUPRECHT-KARLS-UNIVERSITAT-HEIDELBERG
- Current Assignee Address: CH Basel DE Heidelberg
- Priority: EP11151677 20110121
- International Application: PCT/EP2012/050818 WO 20120119
- International Announcement: WO2012/098207 WO 20120726
- Main IPC: G01N33/50
- IPC: G01N33/50 ; C12Q1/6886 ; G01N33/574 ; A61K31/4245 ; A61K31/4439 ; A61K31/44 ; A61K31/41 ; C12Q1/68 ; G01N33/00
Abstract:
Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a furazanobenzimidazole compound of general formula (I).
Public/Granted literature
- US20140045897A1 USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES Public/Granted day:2014-02-13
Information query
IPC分类:
